SEARCH

SEARCH BY CITATION

References

  • 1
    Zakarija M, McKenzie JM. The spectrum and significance of autoantibodies reacting with the thyrotropin receptor. Endocrinol Metab Clin North Am 1988; 16:34363.
  • 2
    Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf) 2003; 58:2807.
  • 3
    Salvi M, Pedrazzoni M, Girasole G et al. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000; 143:197202.
  • 4
    Salvi M, Girasole G, Pedrazzoni M et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 1996; 81:29769.
  • 5
    Antonelli A, Rotondi M, Ferrari SM et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006; 91:61420.
  • 6
    Bahn RS. Clinical review 157: pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003; 88:193946.
  • 7
    Gerding MN, Van Der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2000; 52:26771.
  • 8
    Tsui S, Naik V, Hoa N et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 2008; 181:4397405.
  • 9
    Eckstein AK, Plicht M, Lax H et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91:346470.
  • 10
    De Bellis A, Sansone D, Coronella C et al. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2005; 62:249.
  • 11
    Mikozami T, Salvi M, Wall JR. Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest 2004; 27:221.
  • 12
    Gopinath B, Musselman R, Adams CL, Tani J, Beard N, Wall JR. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features. Thyroid 2006; 16:96774.
  • 13
    Salvi M, Vannucchi G, Campi I et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD 20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156:3340.
  • 14
    Khanna D, Chong KK, Afifiyan NF et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010; 117:1339.
  • 15
    European Group on Graves' Orbitopathy (EUGOGO), Wiersinga WM, Perros P et al. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006; 155:3879.
  • 16
    Mourits MP, Prummel MF, Wiersinga WM, Koorneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997; 47:914.
  • 17
    Werner SC. Classification of the eye changes of Graves' disease. J Clin Endocrinol Metab 1969; 29:9824.
  • 18
    Bartalena L, Baldeschi L, Dickinson AJ et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008; 18:33346.
  • 19
    Persani L, Tonacchera M, Beck-Peccoz P et al. Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. J Endocrinol Invest 1993; 16:51119.
  • 20
    Radetti G, Persani L, Moroder W, Cortelazzi D, Gentili L, Beck-Peccoz P. Transplacental passage of anti-thyroid auto-antibodies in a pregnant woman with auto-immune thyroid disease. Prenat Diagn 1999; 19:46871.
  • 21
    Salvi M, Vannucchi G, Campi I et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 2009; 131:3605.
  • 22
    El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009; 130:2528.
  • 23
    Salvi M, Vannucchi G, Campi I et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006; 154:51117.
  • 24
    El Fassi D, Clemmensen O, Nielsen CH, Silkiss RZ, Hegedüs L. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. J Clin Endocrinol Metab 2007; 92:37623.
  • 25
    Golay J, Cittera E, Di Gaetano N et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006; 91:17683.
  • 26
    Ferraro AJ, Drayson MT, Savage CO, MacLennan IC. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol 2008; 38:2928.
  • 27
    Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66:193348.
  • 28
    Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007; 3:8695.
  • 29
    Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:257281.
  • 30
    Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16:1805.
  • 31
    Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 ‘what do B-cells do?’. Clin Immunol 2005; 117:20713.
  • 32
    Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17:5507.
  • 33
    Salvi M, Bernard N, Miller A, Zhang ZG, Gardini E, Wall JR. Prevalence of antibodies reactive with a 64 kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy. Thyroid 1991; 1:20713.
  • 34
    Gunji K, De Bellis A, Kubota S et al. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1999; 84:125562.
  • 35
    Male D, Cooke A, Owen M, Trowsdale J, Champion B. Antigen receptor molecules. In: MaleD, CookeA, OwenM, TrowsdaleJ, ChampionB, eds. Advanced immunology. London: Mosby, 1996:2.12.2.
  • 36
    Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20:4449.
  • 37
    Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98:9527.
  • 38
    Introna M, Golay J, Barbui T. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura? Haematologica 2003; 88:4824.
  • 39
    Harjunpää A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51:63441.
  • 40
    Treon SP, Agus TB, Link B et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 2001; 24:2729.
  • 41
    Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35:217583.